Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4456263 | 0.98 | KDM4E (0.47) | KDM4EALDH1A1PLD1ADRB2NCF1 | |
| SCHEMBL1271673 | 0.88 | KDM4E (0.41) | KDM4EALDH1A1PLD1ADRB2NCF1 | |
| SCHEMBL300491 | 0.83 | ALOX15 (0.41) | KDM4EALDH1A1ALOX15 | |
| SCHEMBL311710 | 0.81 | BCHE (0.42) | ALDH1A1HRH3ALOX15 | |
| Hydrochloric Acid SCHEMBL9200760 | 0.81 | ALOX15 (0.39) | KDM4EALDH1A1HTR2CHTR2AALOX15 | |
| Hydrochloric Acid SCHEMBL29375122 | 0.79 | BCHE (0.41) | KDM4EALDH1A1HRH3ALOX15 | |
| SCHEMBL6840293 | 0.78 | NPC1 (0.41) | HTR3AHRH3HTR6 | |
| SCHEMBL6904489 | 0.78 | TP53 (0.45) | KDM4EALOX15 | |
| SCHEMBL21047581 | 0.76 | HIPK2 (0.42) | ALDH1A1ALOX15 | |
| SCHEMBL5891722 | 0.75 | HIPK2 (0.37) | ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059305-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | Novartis Ag (CH) | 2009-05-20 | — | — | EP | claimed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | claimed |
| WO-2008014307-A2 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-1381594-A1 | UREA COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | claimed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | claimed |
| JP-7033744-A | — | — | None | — | — | JP | disclosed |
| CN-120192314-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-118103366-A | Certain 2, 5-diazabicyclo [4.2.0] octanes as GLP-1 receptor modulators | 阿斯利康(瑞典)有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117946111-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ANGION BIOMEDICA CORP. | 2022-09-08 | — | — | US | disclosed |
| CN-114502163-A | Ethynylheterocycles as RHO-related coiled coil kinase (ROCK) inhibitors | 安吉昂生物医药公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3290101-A1 | METHOD FOR PRODUCING SUBSTANCE-SELECTIVE SEPARATING MEMBRANES AND THEIR USE | Nanoscience for life GmbH & Co. KG (DE) | 2018-03-07 | — | — | EP | disclosed |
| JP-H0733744-A | IMIDAZOLE DERIVATIVE AND ITS SALT | MEIJI SEIKA KAISHA LTD | 1995-02-03 | — | — | JP | disclosed |
| EP-0300726-B1 | PIPERAZINYL DERIVATES OF PURINES AND ISOSTERES THEREOF AS HYPOGLYCEMIC AGENTS | MERCK & CO. INC. (US) | 1993-09-22 | — | — | EP | disclosed |
| EP-0233051-B1 | ANTIARRHYTHMIC AGENTS | Pfizer Limited (GB) | 1993-09-15 | — | — | EP | disclosed |
| EP-0216775-B1 | CARBOXYLIC ACID ESTER DERIVATIVES OF DEGLUCOTEICOPLANIN | GRUPPO LEPETIT S.p.A. (IT) | 1989-05-03 | — | — | EP | disclosed |
| US-4806536-A | Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents | PFIZER, INC. (US) | 1989-02-21 | — | — | US | disclosed |
| EP-0300726-A1 | Piperazinyl derivates of purines and isosteres thereof as hypoglycemic agents | MERCK & CO. INC. (US) | 1989-01-25 | — | — | EP | disclosed |
| CN-87100652-A | ANTI-DYSRHYTHMIA AGENTS | — | 1987-08-19 | — | — | CN | disclosed |
| US-4588811-A | GREENISH YELLOW DYES FOR PAPER | CIBA-GEIGY CORPORATION (US) | 1986-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281841-A1 | ETHYNYLHETEROCYCLES AS RHO-ASSOCIATED COILED-COIL KINASE (ROCK) INHIBITORS | ROCK1, ROCK2, CIT | KDM4E 2774/4885ALDH1A1 3568/4885PLD1 1637/4885 |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ADRA2C, ADRB2, ADRA2A | KDM4E 3808/4885ALDH1A1 568/4885PLD1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.